As of 2025-05-18, the Intrinsic Value of Kiwa Bio-Tech Products Group Corp (KWBT) is 0.04 USD. This KWBT valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.00 USD, the upside of Kiwa Bio-Tech Products Group Corp is 20,425.00%.
The range of the Intrinsic Value is 0.03 - 0.07 USD
Based on its market price of 0.00 USD and our intrinsic valuation, Kiwa Bio-Tech Products Group Corp (KWBT) is undervalued by 20,425.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 0.03 - 0.07 | 0.04 | 20425.0% |
| DCF (Growth 10y) | 0.02 - 0.04 | 0.03 | 13570.5% |
| DCF (EBITDA 5y) | (0.03) - (0.03) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (0.02) - (0.03) | (1,234.50) | -123450.0% |
| Fair Value | -0.12 - -0.12 | -0.12 | -58,842.25% |
| P/E | (0.21) - (0.31) | (0.26) | -130214.3% |
| EV/EBITDA | 0.02 - 0.06 | 0.04 | 21104.7% |
| EPV | 0.16 - 0.21 | 0.18 | 91518.0% |
| DDM - Stable | (0.02) - (0.18) | (0.10) | -51184.0% |
| DDM - Multi | (0.01) - (0.07) | (0.01) | -6273.4% |
| Market Cap (mil) | 0.06 |
| Beta | 6.58 |
| Outstanding shares (mil) | 282.39 |
| Enterprise Value (mil) | 2.88 |
| Market risk premium | 4.60% |
| Cost of Equity | 41.98% |
| Cost of Debt | 4.25% |
| WACC | 3.43% |